For the year ending 2025-12-31, COCP had -$2,835K decrease in cash & cash equivalents over the period. -$8,204K in free cash flow.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -8,831 |
| Depreciation and amortization expense | 72 |
| Right of use assets | 304 |
| Stock-based compensation | 270 |
| Change in operating lease liabilities | 301 |
| Tax credit receivable | -509 |
| Prepaid expenses and other current assets | -102 |
| Deposits | 66 |
| Accounts payable and accrued expenses | -251 |
| Net cash used in operating activities | -8,192 |
| Purchases of property and equipment | 12 |
| Net cash used in investing activities | -12 |
| Proceeds from the sale of common stock under atm | 154 |
| Proceeds from sale of common stock and warrants, net of transaction costs | 5,215 |
| Net cash provided by financing activities | 5,369 |
| Net decrease in cash and restricted cash | -2,835 |
| Cash and restricted cash at beginning of period | 9,935 |
| Cash and restricted cash at end of period | 7,100 |
Cocrystal Pharma, Inc. (COCP)
Cocrystal Pharma, Inc. (COCP)